Join our daily newsletter At The Bell to receive exclusive market insights
- 4DMedical (4DX) begins the commercial rollout of its XV Lung Ventilation Analysis Software with I-MED Radiology Network
- The software rollout is set to be rapidly expanded to include sites in Brisbane and Wagga Wagga in early 2022 and at selected locations across I-MED’s network thereafter
- The commercial arrangement follows the completion of a year-long piloting program by 4DMedical in collaboration with I-MED
- 4DX says it’s sitting in a strong cash position with $72.2 million in the bank as at 30 September 2021
- 4DMedical was up 17.5 per cent, trading at $1.41 at 11:15 am AEDT
4DMedical (4DX) has begun the commercial rollout of its XV Lung Ventilation Analysis Software with I-MED Radiology Network.
4DX’s technology can accurately and quickly scan lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and monitor changes over time.
The commercial arrangement follows the completion of a year-long piloting program by 4DMedical in collaboration with I-MED, Australia’s largest diagnostic imaging provider.
Beginning in December, clinicians and specialists will be able to refer patients to I-MED’s imaging clinic in Melbourne, where radiology tech compatible with 4DMedical’s XV Technology has been proven in commercial pilot evaluation studies.
“People living with or concerned about respiratory disease will have access to the world’s most advanced four-dimensional quantification and visualisation of their lungs, enabling them and their referring doctor to gain insights into lung function with the highest sensitivity,” 4DMedical’s Managing Director and Chief Executive Officer Andreas Fouras said.
4DMedical’s XV LVAS software rollout is set to be rapidly expanded to include sites in Brisbane and Wagga Wagga in early 2022, and at selected locations across I-MED’s network thereafter.
“This service enables superior information to be provided to patients presenting with lung disorders and will help referring medical practitioners plan appropriate treatment plans,” I-MED’s General Manager Government Relations and External Partnerships, Mark Simpson said.
The rollout will begin at Berwick clinic in Melbourne in December 2021.
The company said it’s sitting in a strong cash position with $72.2 million held as at 30 September 2021 and is well-funded to scale up and execute its commercialisation opportunities.
4DMedical was up 17.5 per cent, trading at $1.41 at 11:15 am AEDT.
